

## CLAIMS

1. One or more chemical entities selected from 7-[4-(4-chlorobenzoyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepinium maleate and a pharmaceutically acceptable solvate thereof.  
5
2. One or more chemical entities selected from 7-[4-(4-chlorobenzoyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepinium tosylate and a pharmaceutically acceptable solvate thereof.  
10
3. A chemical entity according to claim 1 wherein the ratio of 7-[4-(4-chlorobenzoyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine to maleic acid (by mole) is 1:1.
- 15 4. A chemical entity according to claim 2 wherein the ratio of 7-[4-(4-chlorobenzoyloxy)benzenesulfonyl]-8-methoxy-3-methyl-2,3,4,5-tetrahydro-1*H*-3-benzazepine to p-toluenesulfonic acid (by mole) is 1:1.
- 20 5. A chemical entity according to any of claims 1 to 4 in crystalline form.
6. A pharmaceutical composition comprising a chemical entity as claimed in any of claims 1 to 5 and a pharmaceutically acceptable carrier.
- 25 7. A chemical entity according to any of claims 1 to 5 for use in therapy.
8. A chemical entity according to any of claims 1 to 5 for use in the treatment of a psychotic disorder.
9. Use of a chemical entity according to any of claims 1 to 5 in the manufacture of a  
30 medicament for the treatment of a psychotic disorder.
10. A method of treatment of a psychotic disorder in mammals including humans, which comprises administering to a mammal in need thereof an effective amount of a chemical entity according to any of claims 1 to 5.